0001188112-13-003621.txt : 20131227 0001188112-13-003621.hdr.sgml : 20131227 20131227173005 ACCESSION NUMBER: 0001188112-13-003621 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20131227 DATE AS OF CHANGE: 20131227 GROUP MEMBERS: ALFRED SCHEIDEGGER GROUP MEMBERS: NEXTECH III GP LTD. GROUP MEMBERS: ROLAND RUCKSTUHL GROUP MEMBERS: RUDOLF GYGAX SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TETRALOGIC PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001361248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-87773 FILM NUMBER: 131301300 BUSINESS ADDRESS: STREET 1: 343 PHOENIXVILLE PIKE CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 610-889-9900 MAIL ADDRESS: STREET 1: 343 PHOENIXVILLE PIKE CITY: MALVERN STATE: PA ZIP: 19355 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Nextech III Oncology, LPCI CENTRAL INDEX KEY: 0001595470 IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: SCHEUCHZERSTRASSE 35 CITY: ZURICH STATE: V8 ZIP: 8006 BUSINESS PHONE: 410443666612 MAIL ADDRESS: STREET 1: SCHEUCHZERSTRASSE 35 CITY: ZURICH STATE: V8 ZIP: 8006 SC 13G 1 t78022_13g.htm SCHEDULE 13G

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G
(Rule 13d-102)
 
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b),
(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
(Amendment No. _____) *
 
 
 
 TetraLogic Pharmaceuticals Corporation
 (Name of Issuer)
 
 Common Stock
 (Title of Class of Securities)
 
 88165U109
 (CUSIP Number)
 
 December 17, 2013
 (Date of Event Which Requires Filing of This Statement)
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
 
o
 Rule 13d-1(b)
 
      x Rule 13d-1(c)
 
 
o
 Rule 13d-1(d)
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
 

 

 
  CUSIP NO.  88165U109
13 G
Page 2 of 10 Pages
         
  
  1
 
  NAMES OF REPORTING PERSONS
  Nextech III Oncology, LPCI
 
  
  
  2
 
  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o   (b) x (1)
 
  
  
  3
 
  SEC USE ONLY
 
  
  
  4
 
  CITIZENSHIP OR PLACE OF ORGANIZATION
  Switzerland
 
  
 
NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
  
  5
 
  SOLE VOTING POWER
  1,133,919 shares
  
 
  
  6
 
  SHARED VOTING POWER
  0 shares
 
  
 
  
  7
 
  SOLE DISPOSITIVE POWER
  1,133,919 shares
 
  
 
  
  8
 
  SHARED DISPOSITIVE POWER
  0 shares
 
  
  
  9
 
  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
  REPORTING PERSON                                                                     1,133,919 shares of Common Stock
  
  
  10
 
  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
  EXCLUDES CERTAIN SHARES* 
 
 
 
          o
  
  11
 
  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
6.09%(2)
 
  
  
  12
 
  TYPE OF REPORTING PERSON*
PN
 
  
(1)  
This Schedule 13G is filed by Nextech III Oncology, LPCI (“Nextech III LP”), Nextech III GP Ltd. (“Nextech III GP”), Alfred Scheidegger (“Scheidegger”), Rudolf Gygax (“Gygax”)  and Roland Ruckstuhl (“Ruckstuhl” together with Nextech III LP, Nextech III GP, Scheidegger and Gygax, collectively, the “Reporting Persons”).  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
(2)  
The 1,133,919 shares of Common Stock held by the Reporting Person represent 6.09% of the Issuer’s outstanding Common Stock as of December 17, 2013, based on a total of 18,612,256 shares of Common Stock outstanding as of December 17, 2013, as reported by the Issuer to the Reporting Person.
 
 
 

 

 
  CUSIP NO.  88165U109
13 G
Page 3 of 10 Pages
         
  
  1
 
  NAMES OF REPORTING PERSONS
  Nextech III GP Ltd.
 
  
  
  2
 
  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o   (b) x (1)
 
  
  
  3
 
  SEC USE ONLY
 
  
  
  4
 
  CITIZENSHIP OR PLACE OF ORGANIZATION
  Switzerland
 
  
 
NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
  
  5
 
  SOLE VOTING POWER
  1,133,919 shares
  
 
  
  6
 
  SHARED VOTING POWER
  0 shares
 
  
 
  
  7
 
  SOLE DISPOSITIVE POWER
  1,133,919 shares
 
  
 
  
  8
 
  SHARED DISPOSITIVE POWER
  0 shares
 
  
  
  9
 
  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
  REPORTING PERSON                                                                     1,133,919 shares
  
  
  10
 
  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
  EXCLUDES CERTAIN SHARES* 
 
 
 
          o
  
  11
 
  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
6.09%(2)
 
  
  
  12
 
  TYPE OF REPORTING PERSON*
OO
 
 
 
(1)  
This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
(2)  
The 1,133,919 shares of Common Stock held by the Reporting Person represent 6.09% of the Issuer’s outstanding Common Stock as of December 17, 2013, based on a total of 18,612,256 shares of Common Stock outstanding as of December 17, 2013, as reported by the Issuer to the Reporting Person.
 
 
 

 

 
  CUSIP NO.  88165U109
13 G
Page 4 of 10 Pages
         
  
  1
 
  NAMES OF REPORTING PERSONS
  Alfred Scheidegger
 
  
  
  2
 
  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o   (b) x (1)
 
  
  
  3
 
  SEC USE ONLY
 
  
  
  4
 
  CITIZENSHIP OR PLACE OF ORGANIZATION
  Switzerland
 
  
 
NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
  
  5
 
  SOLE VOTING POWER
  0 shares
 
  
 
  
  6
 
  SHARED VOTING POWER
  1,133,919 shares
  
 
  
  7
 
  SOLE DISPOSITIVE POWER
  0 shares
 
  
 
  
  8
 
  SHARED DISPOSITIVE POWER
  1,133,919 shares
 
  
  
  9
 
  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
  REPORTING PERSON                                                                     1,133,919 shares
  
  
  10
 
  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
  EXCLUDES CERTAIN SHARES* 
 
 
 
          o
  
  11
 
  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
6.09%(2)
 
  
  
  12
 
  TYPE OF REPORTING PERSON*
IN
 
 
 
 
(1)  
This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
(2)  
The 1,133,919 shares of Common Stock held by the Reporting Person represent 6.09% of the Issuer’s outstanding Common Stock as of December 17, 2013, based on a total of 18,612,256 shares of Common Stock outstanding as of December 17, 2013, as reported by the Issuer to the Reporting Person.
 
 
 

 

 
  CUSIP NO.  88165U109
13 G
Page 5 of 10 Pages
         
  
  1
 
  NAMES OF REPORTING PERSONS
  Rudolf Gygax
 
  
  
  2
 
  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o   (b) x (1)
 
  
  
  3
 
  SEC USE ONLY
 
  
  
  4
 
  CITIZENSHIP OR PLACE OF ORGANIZATION
  Switzerland
 
  
 
NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
  
  5
 
  SOLE VOTING POWER
  0 shares
 
  
 
  
  6
 
  SHARED VOTING POWER
  1,133,919 shares
  
 
  
  7
 
  SOLE DISPOSITIVE POWER
  0 shares
 
  
 
  
  8
 
  SHARED DISPOSITIVE POWER
  1,133,919 shares
 
  
  
  9
 
  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
  REPORTING PERSON                                                                     1,133,919 shares
  
  
  10
 
  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
  EXCLUDES CERTAIN SHARES* 
 
 
 
          o
  
  11
 
  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
6.09%(2)
 
  
  
  12
 
  TYPE OF REPORTING PERSON*
IN
 
 
 
 
 
(1)  
This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
(2)  
The 1,133,919 shares of Common Stock held by the Reporting Person represent 6.09% of the Issuer’s outstanding Common Stock as of December 17, 2013, based on a total of 18,612,256 shares of Common Stock outstanding as of December 17, 2013, as reported by the Issuer to the Reporting Person.
 
 
 

 

 
  CUSIP NO.  88165U109
13 G
Page 6 of 10 Pages
         
  
  1
 
  NAMES OF REPORTING PERSONS
  Roland Ruckstuhl
 
  
  
  2
 
  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o   (b) x (1)
 
  
  
  3
 
  SEC USE ONLY
 
  
  
  4
 
  CITIZENSHIP OR PLACE OF ORGANIZATION
  Switzerland
 
  
 
NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
  
  5
 
  SOLE VOTING POWER
  0 shares
 
  
 
  
  6
 
  SHARED VOTING POWER
  1,133,919 shares
  
 
  
  7
 
  SOLE DISPOSITIVE POWER
  0 shares
 
  
 
  
  8
 
  SHARED DISPOSITIVE POWER
  1,133,919 shares
 
  
  
  9
 
  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
  REPORTING PERSON                                                                     1,133,919 shares
  
  
  10
 
  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
  EXCLUDES CERTAIN SHARES* 
 
 
 
          o
  
  11
 
  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
6.09%(2)
 
  
  
  12
 
  TYPE OF REPORTING PERSON*
IN
 
 
 
 
 
(1)  
This Schedule 13G is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
(2)  
The 1,133,919 shares of Common Stock held by the Reporting Person represent 6.09% of the Issuer’s outstanding Common Stock as of December 17, 2013, based on a total of 18,612,256 shares of Common Stock outstanding as of December 17, 2013, as reported by the Issuer to the Reporting Person.
 
 
 

 

 
Introductory Note:  This statement on Schedule 13G is filed by the Reporting Persons with the Commission in respect of shares of Common Stock (“Common Stock”), of TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Issuer”).

Item 1
 
(a)
Name of Issuer:
TetraLogic Pharmaceuticals Corporation
 
(b)          
Address of Issuer’s
   Principal Executive Offices:
 
343 Phoenixville Pike
Malvern, PA 19355
 
Item 2
 
(a)
Name of Reporting Persons Filing:

 
1.  
Nextech III Oncology, LPCI (“Nextech III LP”)
 
2.  
Nextech III GP Ltd. (“Nextech III GP”)
 
3.  
Alfred Scheidegger (“Scheidegger”)
 
4.  
Rudolf Gygax (“Gygax”)
 
5.  
Roland Ruckstuhl (“Ruckstuhl”)

(b)
Address of Principal Business Office:
c/o Nextech Invest Ltd.
Scheuchzerstrasse 35
8006 Zurich
Switzerland
 
(c)
Citizenship:

Nextech III LP
Switzerland
Nextech III GP
Switzerland
Scheidegger
Switzerland
Gygax
Switzerland
Ruckstuhl
Switzerland

(d)
   Title of Class of Securities:
Common Stock

(e)
   CUSIP Number:
88165U109
 
Item 3
Not applicable.
 
 
 

 

 
Item 4
Ownership.
 
The following information with respect to the beneficial ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 17, 2013:
 
Reporting Persons
  
Shares Held Directly (1)
  
Sole Voting Power
  
Shared
Voting
Power (1)
  
Sole
Dispositive
Power
  
Shared Dispositive
Power (1)
  
Beneficial Ownership
(1)
  
Percentage of
Class (1, 3)
Nextech III LP
  
1,133,919
  
1,133,919
  
0
  
1,133,919
  
0
  
1,133,919
  
6.09%
                             
Nextech III GP (2)
  
0
  
1,133,919
  
0
  
1,133,919
  
0
  
1,133,919
  
6.09%
                             
Scheidegger (2)
  
0
  
0
  
1,133,919
  
0
  
1,133,919
  
1,133,919
  
6.09%
                             
Gygax (2)
  
0
  
0
  
1,133,919
  
0
  
1,133,919
  
1,133,919
  
6.09%
                             
Ruckstuhl (2)
  
0
  
0
  
1,133,919
  
0
  
1,133,919
  
1,133,919
  
6.09%
 
(1)    
Consists of 1,133,919 shares of Common Stock of the Issuer.
(2)    
The shares are held by Nextech III LP.  Nextech III GP serves as the sole general partner of Nextech III LP and has sole voting and investment control over the shares owned by Nextech III LP and may be deemed to own beneficially the shares held by Nextech III LP.  Nextech III GP owns no securities of the Issuer directly.  Scheidegger, Gygax and Ruckstuhl are managing members of Nextech III GP and share voting and dispositive power over the shares held by Nextech III LP, and may be deemed to own beneficially the shares held by Nextech III LP.  The managing members own no securities of the Issuer directly.
(3)    
The 1,133,919 shares of Common Stock held by the Reporting Person represent 6.09% of the Issuer’s outstanding Common Stock as of December 17, 2013, based on a total of 18,612,256 shares of Common Stock outstanding as of December 17, 2013, as reported by the Issuer to the Reporting Person.

Item 5             Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:      ¨

Item 6
Ownership of More Than Five Percent on Behalf of Another Person.

Not applicable.

Item 7
Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.
 
 
Not applicable.
 
Item 8
Identification and Classification of Members of the Group.
 
 
Not applicable.
 
Item 9
Notice of Dissolution of Group.
 
 
Not applicable.
 
Item 10        Certification.

 
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
 
 
 

 

 
SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in the attached statement on Schedule 13G is true, complete and correct.

Dated: December 27, 2013

NEXTECH III ONCOLOGY, LPCI

By: Nextech III GP Ltd.
Its: General Partner
 
By:  /s/ Alfred Scheidegger  
   Alfred Scheidegger, Managing Member  
     
By: /s/ Rudolf Gygax  
  Rudolf Gygax, Managing Member  
 
NEXTECH III GP LTD.
 
By:   /s/ Alfred Scheidegger  
  Alfred Scheidegger, Managing Member  
     
  /s/ Alfred Scheidegger  
   Alfred Scheidegger  
     
  /s/ Rudolf Gygax  
   Rudolf Gygax  
     
  /s/ Roland Ruckstuhl  
   Roland Ruckstuhl  
 
Exhibit(s):

A:           Joint Filing Statement
 

 

 

 
 

 

 

 

 

 

 

 

 

 
CUSIP No. 88165U109
  
13G
  
Exhibit A
 
EXHIBIT A

JOINT FILING STATEMENT
 
We, the undersigned, hereby express our agreement that the attached statement on Schedule 13G relating to the Common Stock of TetraLogic Pharmaceuticals Corporation is filed on behalf of each of us.

Dated: December 27, 2013

NEXTECH III ONCOLOGY, LPCI

By: Nextech III GP Ltd.
Its: General Partner
 
By:   /s/ Alfred Scheidegger  
  Alfred Scheidegger, Managing Member  
     
By: /s/ Rudolf Gygax  
  Rudolf Gygax, Managing Member  
                                                            
NEXTECH III GP LTD.
 
By:  /s/ Alfred Scheidegger  
  Alfred Scheidegger, Managing Member  
     
  /s/ Alfred Scheidegger  
   Alfred Scheidegger  
     
  /s/ Rudolf Gygax  
   Rudolf Gygax  
     
  /s/ Roland Ruckstuhl  
   Roland Ruckstuhl